Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001733428 | SCV001983784 | likely pathogenic | not provided | 2025-03-06 | criteria provided, single submitter | clinical testing | In a preprint by Ferrer et al. (2023), the variant was reported as de novo in a patient with global developmental delay, failure to thrive, seizures, thinning of the optic chiasm, and mild atrophy of the optic nerves. Ferrer A et al. https://doi.org/10.21203/rs.3.rs-3146571/v1; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35982159, 37541188, Ferrer2023[Preprint], 33057194) |
Labcorp Genetics |
RCV001733428 | SCV003323743 | pathogenic | not provided | 2022-12-29 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AFG3L2 protein function. ClinVar contains an entry for this variant (Variation ID: 1301415). This missense change has been observed in individual(s) with clinical features of autosomal dominant spinocerebellar ataxia (Invitae). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 407 of the AFG3L2 protein (p.Asp407Asn). |
Revvity Omics, |
RCV001733428 | SCV003820533 | uncertain significance | not provided | 2021-09-03 | criteria provided, single submitter | clinical testing |